1681 (1681) Fair Value & Analysis

Healthcare · Market cap HK$11.0B

1 1681 1681 · HK

PriceHK$13.13

Fair ValueHK$25.71

Upside+95.8%

Quality67/100

Watch 1681 for free — get notified when fair value or trend changes. Watch for free

Evidence: Medium Range HK$19.60 – HK$42.51

Fair value as of: Jul 2, 2026

From 26 valuation models · updated today

Share price −6.0% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$10.52 – HK$18.82 · fair‑value band HK$19.60 – HK$42.51 · the HK$13.13 price screens below the HK$25.71 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1681 (1681) currently trades at HK$13.13, while our model-based Fair Value estimate is HK$25.71 — implying the stock looks roughly 95.8% undervalued today. We read business quality at 67/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

Over the trailing twelve months, 1681 generated revenue of HK$3.4B at a net margin of 31.6%. Revenue grew 8.8% year over year. It earns a return on equity of 23.6%. The balance sheet holds a net cash position of HK$1.1B. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$3.4B

Revenue growth (YoY) +8.8%

Net margin 31.6%

Return on equity 23.6%

Free cash flow HK$1.1B FY2025

P/E ratio 9.1

More key figures

Operating margin 34.5%

EPS (TTM) HK$0.5800

Dividend yield 5.2%

EPS growth (YoY) +13.9%

Net cash HK$1.1B FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

1681 reported revenue of HK$3.4B in FY2025 versus HK$2.0B in FY2021, a compound +13.7%/yr. Reported net income was HK$1.1B in FY2025, compounding +16.3%/yr from FY2021.

Revenue +13.7%/yr

FY21 HK$2.0B

FY22 HK$2.3B

FY23 HK$2.6B

FY24 HK$3.0B

FY25 HK$3.4B

Net income +16.3%/yr

FY21 HK$590M

FY22 HK$683M

FY23 HK$785M

FY24 HK$910M

FY25 HK$1.1B

Is 1681 fairly valued? → Check now

Similar stocks

6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
1276 1276	HK$57.85	HK$29.84	-48%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥47.01	¥26.59	-43%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,782	₹915.92	-49%
Zoetis Inc Z1TS34	R$24.45	R$6.33	-74%
Hansoh Pharmaceutical Group 3692	HK$29.58	HK$18.75	-37%
Divi's Laboratories Limited DIVISLAB	₹6,788	₹2,035	-70%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 1681 (1681) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$25.71 versus a price of HK$13.13 — about +96% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 1681?

Our model-based fair value for 1681 is HK$25.71 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$13.13.

What is the quality score of 1681?

1681 has a Quality Score of 67/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 1681 (1681)?

1681 reported trailing-twelve-month revenue of about HK$3.4B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 1681?

The net profit margin of 1681 is about 31.6%, meaning it keeps roughly 31.6% of revenue as net income. Based on the latest reported figures.

Does 1681 pay a dividend?

1681 currently shows a dividend yield of about 5.21% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.